

AD _____

Award Number: DAMD17-00-1-0457

TITLE: Involvement of BRCA2 BRC Repeats in RAD51 Mediated DNA Repair

PRINCIPAL INVESTIGATOR: Qing Gao, M.D., Ph.D.
Nicholas Ting, Ph.D.
Wen-Hwa Lee, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas
Health Sciences Center at San Antonio
San Antonio, Texas 78229-3900

REPORT DATE: December 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030411 029

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE December 2002	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Dec 01 - 30 Nov 02)	
4. TITLE AND SUBTITLE Involvement of BRCA2 BRC Repeats in RAD51 Mediated DNA Repair			5. FUNDING NUMBERS DAMD17-00-1-0457	
6. AUTHOR(S) Qing Gao, M.D., Ph.D. Nicholas Ting, Ph.D. Wen-Hwa Lee, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas Health Sciences Center at San Antonio San Antonio, Texas 78229-3900 E-Mail: gaoq@uthscsa.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates: All DTIC reproductions will be in black and white.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Mutations in the BRCA2 gene have been found in many familial breast cancers. Cells deficient for functional BRCA2 show various cellular abnormalities including increased sensitivity to genotoxic agents, accumulation of DNA double-strand breaks, chromosome abnormalities, and changes in cell cycle checkpoint and apoptotic responses. These observations suggest a role for BRCA2 in DNA repair. This postulation was further supported by data showing that BRCA2 interacts with RAD51, a protein involved in DNA recombination repair. RAD51 associates with BRCA2 through the highly conserved BRC repeats within the middle region of the BRCA2 protein. We have shown that ectopic expression of the BRC repeat in MCF-7 cells resulted in increased cellular sensitivity to radiation, an inability to form RAD51 radiation foci, and a loss of radiation-induced G2/M checkpoint control. Further, we have purified the putative Arabidopsis homologue of BRCA2 in order to determine the precise molecular mechanism of BRCA2's role in RAD51 mediated recombination repair. As well, BRC-tat peptide has been generated to explore the possibility of making tumor cells more susceptible to radiation treatment. The results of these experiments will provide further insights into understanding and treating BRCA2-linked breast cancers.				
14. SUBJECT TERMS BRCA2, RAD51, DNA repair, breast cancer				15. NUMBER OF PAGES 11
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

TABLE OF CONTENTS:

	Page
FRONT COVER	1
STANDARD FORM 298	2
TABLE OF CONTENTS	3
INTRODUCTION	4
BODY	4,5
REPORTABLE OUTCOMES	6
CONCLUSIONS	6
REFERENCES	6
APPENDICES (Reprints)	7

INTRODUCTION

Mutations to *BRCA2* account for approximately 2-5% of all cases, and 40% of familial cases of breast cancer, respectively [1-3]. The *BRCA2* gene has been mapped to chromosome 13q12-13 [2,4], and it encodes a 384 kDa nuclear protein that is highly expressed in testies, thymus and ovaries [5]. Inactivation of *Brca2*, the mouse homologue, leads to embryonic lethality at an early stage of development, suggesting a role for *BRCA2* in cellular proliferation and differentiation [6,7,8]. Furthermore, *Brca2*-null embryonic fibroblasts show increased sensitivity to genotoxic agents [6], and spontaneous accumulation of chromosomal abnormalities [6,7,8]. These observations implicate a requirement for *BRCA2* in maintaining chromosome stability through a role in DNA repair. Indeed absence of *BRCA2* have been shown to reduce the efficiency the repair of double strand break through the error free repair pathway known as homologous recombination (HR) [9].

Central to the role of *BRCA2* in HR is the interaction with RAD51, the human homologue of the *E.coli* recombination protein Rec A. RAD51 associates with DNA and induces ATP-dependent DNA pairing and strand exchange activity during HR [10,11]. Interactions between *BRCA2* and RAD51 have been demonstrated both in vitro and invivo through yeast two-hybrid system screening and co-immunoprecipitation [6,12,13,14]. The association between these proteins involves direct binding of RAD51 to the conserved BRC repeats located in the middle region of the *BRCA2* protein [12,14]. This evidence therefore suggests that *BRCA2* may regulate the recombinase activity of RAD51 during DNA repair.

We hypothesize that *BRCA2* regulates RAD51 mediated HR through direct interactions with the BRC repeats. To test this hypothesis, we will perform a series of experiments to test cellular responses resulting from the disruption of the BRC repeats in *BRCA2*. First, wild type BRC repeat-GFP fusion proteins will be expressed in cell lines as competitors for RAD51 binding. Second, direct point mutations in the conserved regions of BRC repeats will be utilized to determine the importance of these repeats in DNA repair. Under these conditions, when cells are treated with genotoxic agents, it is possible that they will display abnormalities in cell viability, cell cycle control, apoptosis and chromosome instability. Third, we will examine how *BRCA2* may modulate RAD51 activity by using purified *BRCA2* and RAD51 in *in-vitro* DNA strand pairing and DNA strand exchange assays. Finally, the importance of the BRC repeats of *BRCA2* in DNA repair will be tested *in vivo* by introducing small BRC repeat peptides in MCF7 breast tumor cells. We predict that when these cells are injected into nude mice, the resulting tumors will be more sensitive to genotoxic drugs, compared to tumor cells harboring mutated forms of the BRC peptides. These experiments are outlined in the following four specific aims.

BODY

Aim 1: To test the importance of BRC repeats in BRCA2 for binding to RAD51 in response to DNA damage.

We have shown that ectopic expression of GFP-BRC4 repeat in MCF7 cells blocked the interaction between endogenous RAD51 and *BRCA2*. Consequently, the cells expressing

BRCA4 did not show RAD51 radiation-induced foci, became sensitive to radiation treatment and were unable to arrest at the G2/M checkpoint boundary in response to DNA damage. Refer to the attached publication for details of our results.

Aim 2: *To determine the critical residues in the BRC repeats of BRCA2 and the significance of these residues for BRCA2/RAD51 interactions.*

We have determined that the third residue of the BRC repeat consensus amino acid residue is critical for interaction with RAD51. Mutation of the threonine residue to alanine abrogated the ability of the BRCA4 peptide to interact with RAD51 *in vitro*. Expression of this mutant BRCA4 peptide had no effect on cellular responses to DNA damage. Refer to the attached publication for details of these results.

Aim 3: *To determine if BRCA2, through BRC repeats, directly affects DNA repair mechanisms mediated by RAD51.*

As an initial step towards performing the experiments outlined in this aim, considerable effort was invested into obtaining purified human BRCA2. We were successful in expressing full length BRCA2 containing an N-terminal Histidine tag and a C-terminal HA tag using the sf9 baculovirus protein expression system. However, due to the size of full length human BRCA2 (390 kDa) our chromatographic preparations of BRCA2 were very susceptible to proteolysis. Although some purified human BRCA2 was obtained, the amount was not sufficient for the *in-vitro* DNA strand exchange assays. As a possible solution to our predicament, we have cloned the putative homologue of BRCA2 from *Arabidopsis thaliana* (At) and expressed it as a GST-fusion protein in sf9 cells. Although the similarity in the amino acid sequence of full length AtBRCA2 and human BRCA2 is very little, there is high similarity (about 80%) and conservation in the BRC repeats and the C-terminus region between the two proteins. AtBRCA2 is about 125 kDa and contains four BRC repeats, along with the C-terminal conserved domain. We have purified AtBRCA2 to homogeneity, and preliminary data showed that AtBRCA2 interacted with human RAD51. Therefore, AtBRCA2 will be utilized to address all the issues outlined in this aim.

Aim 4: *To test small BRC repeat peptides in vivo for their ability to overcome tumor resistance to DNA damaging agents.*

To address this aim we have generated both wild type and mutant BRC4 polypeptide fused in frame with the Tat peptide sequence. It has been well documented that heterologous proteins harboring the Tat peptide can be transported across membranes to the cytoplasm and nucleus of cells [15]. We will now introduce the Tat-BRC4 peptide into MCF7 cells, and inject these cells into nude mice to induce tumor formation. The resultant tumors will be treated with radiation. We predict that tumor cells containing wild type BRC4 will interrupt BRCA2 binding with RAD51 and subsequently interfere in the DNA repair pathway causing hypersensitivity in these tumors to genotoxic agents. This is an important step towards exploring the notion of using this BRC peptide as a possible agent to make tumors more responsive to radiation therapy.

REPORTABLE OUTCOMES

Publications:

Chen, C-F., Chen, P-L., Zhong, Q., Sharp, Z.D. and Lee, W-H. (1999) Expression of BRC Repeats in Breast Cancer Cells Disrupt the BRCA2-Rad51 Complex and leads to Radiation Hypersensitivity and Loss of G2/M Checkpoint Control. *Journal of Biological Chemistry*, Vol 274 (46):32931-32935.

CONCLUSIONS

The results presented here have revealed the importance of the BRC repeats in the function of BRCA2 in cellular DNA repair pathway. We have now generated the required reagents, namely purified AtBRCA2 protein and Tat-BRC4 peptide, to further disseminate the molecular mechanism for BRCA2's role in RAD51 mediated homologous recombination and explore the possibility of using BRC4 peptide as part of an anti-tumor therapeutic regiment, respectively. All the experiments outlined in the aims will be accomplished within the year, and we look forward to report our findings.

REFERENCES

1. Claus, E.B., Risch, N., & Thompson, W.D. (1991) *Am. J. Hum. Genet.* **48**, 232-242.
2. Wooster, R. *et al.* (1995) *Nature* (London) **378**, 789-792
3. Futreal, P.A. *et al.* (1994) *Science* **266**, 120-122
4. Tavtigian, S.V. *et al.* (1996) *Nat. Genet.* **12**, 333-337
5. Rajan, J.V., Marquis, S.T., Gardner, H.P., & Chodosh, L.A. (1997) *Dev. Biol.* **184**, 385-401
6. Sharan, S.K., *et al.* (1997) *Nature* (London) **386**, 804-810
7. Ludwig, T., Chapman, D.L., Papaioannou, V.E., & Efstratiadis, A. (1997) *Genes Dev.* **11**, 1226-1241
8. Suzuki, A., *et al.* (1997) *Genes Dev* **11**, 1242-1252.
9. Moynahan, M.E., Pierce, A.J., & Jasin, M. (2001) *Mol Cell* **7**, 263-272
10. Baumann, P., Benson, F.E. & West, S.C. (1996) *Cell* **87**, 757-766
11. Bauman, P., & West, S.C. (1997) *EMBO J* **16**, 5198-5206
12. Chen, P-L., *et al.* (1998) *Proc. Natl. Acad. Sci.* **95**, 5287-5292
13. Mizuta R., *et al.* (1997) *Proc. Natl. Acad. Sci.* **94**, 6927-6932
14. Wong, A.K. *et al.* (1997) *J. Biol. Chem.* **272**, 31941-31944
15. Fawell, S. *et al.* (1994) *Proc. Natl. Acad. Sci.* **91**, 664-668

Expression of BRC Repeats in Breast Cancer Cells Disrupts the BRCA2-Rad51 Complex and Leads to Radiation Hypersensitivity and Loss of G₂/M Checkpoint Control*

(Received for publication, June 10, 1999, and in revised form, August 25, 1999)

Chi-Fen Chen, Phang-Lang Chen, Qing Zhong, Z. Dave Sharp, and Wen-Hwa Lee†

From the Department of Molecular Medicine and Institute of Biotechnology, University of Texas Health Science Center, San Antonio, Texas 78245

BRCA2 is a breast tumor suppressor with a potential function in the cellular response to DNA damage. BRCA2 binds to Rad51 through its BRC repeats. In support of the biological significance of this interaction, we found that the complex of BRCA2 and Rad51 in breast cancer MCF-7 cells was diminished upon conditional expression of a wild-type, but not a mutated, BRC4 repeat using the tetracycline-inducible system. Cells expressing a wild-type BRC4 repeat showed hypersensitivity to γ -irradiation, an inability to form Rad51 radiation-induced foci, and a failure of radiation-induced G₂/M, but not G₁/S, checkpoint control. These results strongly suggest that the interaction between BRCA2 and Rad51 mediated by BRC repeats is critical for the cellular response to DNA damage.

BRCA2 was cloned based on an analysis of mutations in families predisposed to breast cancer showing that a large percentage of the kindred had alterations within this locus (1, 2). The expression pattern of BRCA2 is remarkably similar to that of BRCA1 (3–5), with highest levels in the testis, thymus, and ovaries (5). At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase (6). These results suggest BRCA2 may participate in regulating cell proliferation.

Recent studies indicate that BRCA2 is important for the cellular response to DNA damage. *Brca2*-null mouse embryos are nonviable at a very early stage of development and blastocysts derived from these embryos are very sensitive to γ -irradiation (7). Mouse embryonic fibroblasts predicted to express BRCA2 that is C-terminally truncated at amino acid 1492 also demonstrated sensitivity to DNA damaging agents, particularly methyl methanesulfonate and UV light (8). Furthermore, Capan-1, a human pancreatic cancer line, that expresses a 220-kDa C-terminally truncated BRCA2 protein, is hypersensitive to a panel of DNA damaging agents (9). Importantly, ectopic expression of wild-type, but not mutated, BRCA2 in Capan-1 cells restores resistance to treatment with MMS (10). These results provided convincing evidence that BRCA2 plays a critical role in the DNA repair process.

Interestingly, BRCA2 was shown to interact with Rad51 (7, 10–12), a key protein in DNA recombinational repair. Human Rad51 encodes a 40-kDa protein with a structure related to the

Escherichia coli recombination protein RecA (13) and mediates homologous DNA pairing and strand exchange (14, 15). Similar to *mBrca2*, inactivation of mouse *Rad51* results in an embryonic lethal phenotype, indicating that Rad51 protein is essential for development (16, 17). Beyond serving as a DNA repair protein through its interactions with other Rad proteins including Rad52 and Rad54 (18), how Rad51 may participate in cell growth and development remains unclear.

While an association between BRCA2 and Rad51 is well documented, there is, nonetheless, some discrepancy concerning the regions of BRCA2 that bind to Rad51. It was reported that the C-terminal region of mouse *Brca2* binds to mouse Rad51 (7). By contrast, we and others have previously shown that the BRC repeats located in exon 11 (amino acid 1009–2083) of human BRCA2 bind to Rad51 (10, 12). There are eight repeats in BRCA2 designated as BRC1 to BRC8 (Fig. 1A) (19, 20). BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51 (10, 12). Whether the interaction between BRCA2 and Rad51 has biological significance remains completely unknown. In an effort to investigate this issue, we have used the tetracycline binary gene control system for conditional expression of a BRC4 repeat in breast cancer MCF-7 cells. In this communication, we have found that upon expression of a wild-type, but not a mutated, BRC4 repeat, the interaction between BRCA2 and Rad51 was reduced. Cells expressing a wild-type BRC4 repeat showed hypersensitivity to γ -irradiation, an inability to form radiation-induced Rad51 nuclear foci, and a failure of radiation-induced G₂/M checkpoint control. These results strongly suggest that the BRC repeats of BRCA2 are important for mediating the cellular response to DNA damage.

EXPERIMENTAL PROCEDURES

Mutagenesis and Selection for BRC Mutants—The 39-amino acid BRC1 repeat (residue 1003–1042 of BRCA2) (2) in pBSK (Stratagene, La Jolla, CA) was randomly mutagenized by a biased-pool PCR¹ method (21) using T3 and T7 primers. Deoxynucleotide triphosphates used in PCR reaction were 10 mM dGTP, dCTP, dTTP, and 2 mM dATP. The resulting PCR fragments were digested with *Nco*I and *Xho*I and cloned into pAS1 vector (22) to generate a BRC1 mutant library (pAS1/BRC1-ML). These plasmid DNAs were transformed along with pGAD-Rad51 into the yeast Mav203 strain (MAT α , leu2–3, 112, trp1–901, his3 Δ 200, ade2–101, gal4 Δ , gal80 Δ , SPAL10::URA3, GAL1::lacZ, HIS3UAS GAL1::HIS3@LYS2, can1R, cyh2R) and selected for 5-fluoroorotic acid-resistant colonies (23). The recovered pAS1/BRC DNAs were further sequenced to determine the mutations. β -Galactosidase activities (U) was measured using chlorophenyl-red- β -D-galactopyranoside as substrate for interactions in the yeast two-hybrid system as described (22).

Isolation of Cell Clones with Inducible Expression of the BRC Re-

* This work was supported by Grants CA58183 and CA30195 from the NCI (to W. H. L.) and Grant 9733 from the Susan G. Komen Foundation for Breast Cancer Research (to P. L. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence should be addressed. Tel.: 210-567-7353; Fax: 210-567-7377; E-mail: leew@uthscsa.edu.

¹ The abbreviations used are: PCR, polymerase chain reaction; GFP, green fluorescence protein; DAPI, 4',6-diamidino-2-phenylindole; BrdUrd, bromodeoxyuridine; Tet, tetracycline.

TABLE I
Identification of mutations in the first and fourth BRC repeats of BRCA2 that disrupt binding to Rad51

A randomly mutagenized pool of cDNAs encoding BRC1 repeats (amino acid 1003–1042) was cloned into the pAS1 vector and co-transformed along with pGAD-Rad51 into Mav203 cells. Four clones with DNA inserts that showed no detectable β -galactosidase activity in a yeast two-hybrid assay were isolated. Mutations with amino acid changes resulted from single nucleotide changes. Rad51 binding activity using the BRC4 in pAS1 vector was also tested in the assay. Note that this repeat has 3-fold higher activity compared with the BRC1 repeat. The T to A mutation identified above in the BRC1 repeat that abrogates Rad51 binding, and a familial mutation identified in BRC4 (G1529R) was introduced into the BRC4 and tested in the yeast-two hybrid assay. Both of the mutations significantly reduced, but the G to R mutation did not completely eliminate, Rad51 binding in this assay.

BRC consensus	I I FXTASGKX X SXXXLXKXXX X V V F E	L D	Relative β -galactosidase activity
BRC1	FRTASNKEIKLSEHNIKSKMFFKD		7
BRC1-M1	A		<1
BRC1-M2	G		<1
BRC1-M3		S	<1
BRC1-M4		RG	<1
BRC4	FHTASGKKVKIAKESLDKVNLFDE		22
BRC4-M5	A		<1
BRC4-M6	R		4
vector			1

peat—To generate cell clones that express a GFP-BRC4 fusion protein, we employed the tetracycline-inducible expression system controlled by a *tet*-responsive promoter (24). A pUHD10-3-based plasmid was used to construct pUHD10-3/GFP-BRC plasmids that will express chimeric proteins containing GFP with a nuclear localization signal and a myc epitope fused to either a wild-type BRC4 or a mutated BRC4-M5. These two plasmids were separately co-transfected into MCF-7 cells with the second plasmid, pCHTV, which contains a hygromycin resistance gene and a cytomegalovirus-controlled tetracycline repressor-VP16 fusion transcription unit. Cell clones resistant to hygromycin were subsequently isolated and several of them were shown to express the wild-type or mutant GFP-BRC4 upon removal of tetracycline. The expression of GFP-BRC4 was further confirmed by immunoprecipitation with α -myc 9E10 monoclonal antibody (25) and immunoblotting analysis with a monoclonal α -GFP antibody (CLONTECH, Palo Alto, CA). Two stable lines of MCF-7 cells, WT-8 and MT-11, that conditionally express wild-type BRC4 and BRC4-M5 mutant, respectively, were established.

Immunoprecipitations and Western Blotting—Immunoprecipitations were performed as described previously (10). Co-immunoprecipitations were performed similarly but with lysis buffer containing 180 mM NaCl. Antibodies specific for BRCA2 (10), human Rad51, Ab-1 (Oncogene Science, Cambridge, MA) and myc 1-9E10 monoclonal antibody (25) were used for the immunoblotting analysis according to standard procedure (10).

Immunostaining Rad51 Foci—Procedures for immunostaining were adapted from Zhong *et al.* (26). Briefly, cells in Dulbecco's modified Eagle's medium with or without tetracycline (1 μ g/ml) grown on coverslips to 60–70% confluence were irradiated with 12 Gy using a Mark I, model 68A irradiator. After 6 h, cells were fixed in 4% formaldehyde with 0.1% Triton X-100. α -Rad51 antibody (Ab-1) diluted 1:1000 in 10% goat serum was added onto the cells and then visualized with goat anti-rabbit antibody conjugated to Texas Red. Cells were further stained with 4',6-diamidino-2-phenylindole (DAPI) and mounted in Permafluor (Lipshaw-Immunonon, Pittsburgh, PA). Rad51 foci-positive cells were counted and recorded using a standard fluorescence microscope.

Clonogenic Survival Assay—Cells (WT-8 and MT-11) were seeded in identical plates at 5000 cells/plate in medium with tetracycline (1 μ g/ml). Expression of the wild-type or mutant GFP-BRC4 repeat was induced by removing tetracycline 24 h after seeding. Twenty four hours after induction of GFP-BRC4 expression, cells were then γ -irradiated with 3 Gy. After incubation for 14 days, cells were fixed and stained with 2% methylene blue in 50% of ethanol for colony counting. Averages and standard deviations were determined from eight plates. Statistical analyses were performed with the programs InStat and InPlot (Graph-Pad Inc., San Diego, CA).

Cell Cycle Checkpoint Analysis—The G₂/S checkpoint was determined according to the procedures described (27). Briefly, cells in logarithmic growth were mock-exposed or γ -irradiated (12 Gy). After 24 h, cells were labeled with 10 μ M BrdUrd for 4 h and fixed for BrdUrd staining using a Cell Proliferation Kit (Amersham Pharmacia Biotech). BrdUrd-positive cells were quantified, and expressed as a fraction of the

total cells. For the G₂/M checkpoint, cells were irradiated to 3 Gy, fixed with 4% paraformaldehyde at indicated time and stained with DAPI for counting mitotic cells in prophase, metaphase, anaphase, and telophase (28). Alternately, cells were irradiated with 4–16 Gy and processed for analysis of mitotic cells after 1 h.

RESULTS AND DISCUSSION

To systematically address the biological consequence of the interaction between BRCA2 and Rad51, amino acid residues of the first BRC repeat, BRC1, that are critical for Rad51-binding were first examined. BRC1 was subjected to biased PCR mutagenesis (21), and the mutated cDNAs were translationally fused to the GAL4 DNA-binding domain in the yeast vector, pAS1 (22), to generate a library of 2×10^6 individual clones referred to as pAS/BRC1-ML. A reverse two-hybrid screen with negative selection was used to isolate clones that fail to bind Rad51 as described previously (23). Several mutations in BRC1 were identified that significantly reduced Rad51 binding in a yeast two-hybrid assay (Table I). BRC1-M1 is a mutation that changes a conserved threonine residue to alanine. BRC1-M2 and -M3 are changes in nonconsensus amino acids, and BRC1-M4 carries a double mutation at the two C-terminal BRC1 residues, the last residue of which is conserved. Interestingly, a familial mutation, G1529R, has been previously found in BRC4 (Breast Cancer Information Core). Specific Rad51 binding activity by BRC4 was also tested and found to be approximately three times stronger than BRC1 (Table I). Two BRC4 mutations, BRC4-M5, an analogous mutation to BRC1-M1, in which the conserved threonine at the third position is changed to an alanine, and BRC4-M6, which contains the G1529R mutation, were constructed and found to have reduced Rad51-binding (Table I). These results suggest that, despite their sequence conservation, the ability of BRC repeats to bind Rad51 varies, and is dependent on specific residues.

To determine the functional importance of the interactions between the BRC repeats of BRCA2 and Rad51, two stable lines of MCF-7 cells, WT-8 and MT-11, that conditionally express wild-type BRC4 and mutant BRC4-M5, respectively, were established (Fig. 1B). Tetracycline-responsive expression of the GFP-BRC4 fusion proteins in these two lines was clearly demonstrated by immunoprecipitation with α -myc antibodies and immunoblotting with α -GFP or α -Rad51 antibodies (Fig. 1C, top panel compare lanes 2 and 4 with 1 and 3). Rad51 is detected in the immunoprecipitates of wild-type, but not GFP-BRC4-M5 (Fig. 1C, compare lanes 4 with 2), indicating that the




FIG. 1. Conditional expression of wild-type and mutated GFP-BRC4 fusions in MCF7 cells. **A**, diagram of BRCA2 showing exon 11 and the eight BRC repeats. **B**, the top panel is a schematic drawing illustrating the GFP-BRC4 fusion containing a BRC4 cDNA fragment translationally fused to a myc epitope-GFP-nuclear localization signal cassette in a modified pUHD10-3 plasmid, pUHD10-3/GFP-BRC. The lower panel shows cell clones expressing the wild-type GFP-BRC4 (WT-8) (panels a–d) and mutated GFP-BRC4-M5 (MT-11) (panels e–h) were visualized by GFP autofluorescence (panels a, c, e, and g) after incubation in the presence (panels a, b, e, and f) or absence (panels c, d, g, and h) of tetracycline (Tet). Fluorescence overlaid with phase-contrast images (panels b, d, f, and h) show nuclear localization of these fusion proteins. **C**, co-immunoprecipitation of GFP-BRC4 with Rad51 in cells. Cells expressing wild-type (WT-8) or mutated GFP-BRC4 (MT-11) were immunoprecipitated with α -myc antibody (top two panels), immunoblotted with either α -GFP to detect the GFP-BRC4 fusions or α -Rad51 (indicated in the left margin). Immunoprecipitation and Western blotting with α -Rad51 antibody (bottom panel) determined the relative levels of endogenous Rad51. **D**, expression of wild-type GFP-BRC4 in WT-8 cells reduces the complex formation between BRCA2 and Rad51. Thirty-six hours after induction of GFP-BRC4 expression, cell lysates were co-immunoprecipitated with either α -BRCA2 (top panel) or α -Rad51 antibody (bottom panel). The resulting immune complexes were analyzed by immunoblot analysis with either α -BRCA2 or α -Rad51 antibody, indicated on the left margin.

GFP fusion with wild-type BRC4 binds to Rad51 in cells.

Importantly, expression of wild-type, but not the BRC4-M5 mutant, significantly reduced BRCA2 in the Rad51 immunoprecipitates and, in the reciprocal experiment, reduced Rad51 in the BRCA2 immunoprecipitates (Fig. 1D, compare lane 4 with lane 2). These data strongly suggest that conditional expression of a wild-type, but not a mutated, BRC4 repeat effectively disrupts the interaction between BRCA2 and Rad51.

The important role of Rad51 in recombinational DNA double-strand break repair (13) suggests that disruption of the interaction between BRCA2 and Rad51 may have an adverse effect on the ability of cells to respond to DNA damage. To test this possibility, both WT-8 and MT-11 cells cultured either with or without tetracycline, were mock-exposed or γ -irradiated (3 Gy), and cell survival was determined by clonogenic assay. Induction of the expression of a wild-type BRC4 repeat (WT-8, –Tet) significantly reduced cell survival rate when compared with the uninduced (WT-8, +Tet) or to either the induced (MT-11, –Tet) or uninduced (MT-11, +Tet) mutant BRC4 ($p < 0.0001$) (Table II).

To further explore DNA damage response phenotypes of these two cell lines, the appearance of radiation-induced

TABLE II

Clonogenicity of WT-8 and MT-11 cells after γ -irradiation

Actively growing WT-8 and MT-11 cells (5000) were either induced (–Tet) or uninduced (+Tet) to express GFP-BRC4. About 24 h later, cells were either mock-exposed or γ -irradiated (3 Gy) and cultured for 14 days. Survival rates by colony formation (>50 cells/colony) were determined by counting the number of colonies per plate. Averages and S.D. were calculated from eight plates. Survival rates were calculated by dividing the number of colonies in the mock-exposed control by the number from exposed cells. Note that the expression of wild-type, but not mutated BRC4 repeat, significantly reduced cell survival in this assay ($p < 0.0001$).

	0 Gy	3 Gy	Survival rate, mean \pm S.D. (n = 8)
WT-8 (+Tet)	405 \pm 14	189 \pm 12	46.8 \pm 7.9%
WT-8 (–Tet)	358 \pm 17	72 \pm 2	20.1 \pm 2.0%
MT-11 (+Tet)	371 \pm 10	173 \pm 10	46.8 \pm 8.0%
MT-11 (–Tet)	379 \pm 15	163 \pm 7	43.2 \pm 5.2%

Rad51-containing foci was examined. Under uninduced conditions (+Tet), both clonal lines formed Rad51 foci after γ -irradiation (Fig. 2A). However, WT-8 cells induced to express a wild-type GFP-BRC4 repeat exhibited a reduction in the appearance of Rad51 foci compared with MT-11 cells induced to express the GFP-BRC4-M5 mutated repeat (Fig. 2A for representative field and Fig. 2B for quantification). These data suggest that the interaction between BRCA2 and Rad51 is crucial for the formation of Rad51 repair foci and, furthermore, that exogenous expression of BRC repeats can interfere with this activity.

Increased sensitivity to ionizing radiation may result from defects in the DNA repair machinery or in the molecules essential for cell cycle checkpoint control. When normal mouse embryo fibroblasts are exposed to γ -irradiation, their transit through the cell cycle is arrested at either one of two points (27, 29). The G₁/S checkpoint, dependent on p53 and p21 (29–32), prevents the replication of damaged DNA. The G₂/M checkpoint prevents segregation of damaged chromosomes (33). To test for a potential role of BRCA2-Rad51 interactions in DNA damage-induced cell cycle checkpoint control, cells expressing the GFP-BRC4 repeat were assayed for G₁/S and G₂/M checkpoint integrity in response to γ -irradiation. As shown in Fig. 3A, WT-8 and MT-11 cells, under all conditions, demonstrated nearly identical numbers of BrdUrd-incorporated cells, indicating that the expression of the BRC repeats did not significantly impair G₁/S checkpoint control in response to γ -irradiation.

In contrast, when cells were assayed for mitotic figures at variable times after γ -irradiation, the number of cells in mitosis was not significantly decreased in WT-8 cells induced to express a wild-type BRC4 repeat (Fig. 3B, panel a). However, MT-11 cells induced to express a GFP-BRC4-M5 mutated repeat, as well as uninduced cells, demonstrated significant reductions in mitotic figures (Fig. 3B, panel a). In a parallel experiment, cells were irradiated with 4–16 Gy. In the population induced to express a wild-type BRC4, the percentage of mitotic cells was significantly higher than that of cells either uninduced or induced to express mutant GFP-BRC4-M5 (Fig. 3B, panel b). These results suggest that cellular expression of a wild-type BRC4 repeat interferes with the radiation-induced G₂/M checkpoint.

It was reported that mouse embryo fibroblasts, with a genotype *Brca2*^{tm1Cam} and predicted to express a C-terminally truncated BRCA2 at amino acid 1492, have intact cell cycle checkpoint responses (8). This truncated BRCA2 protein possesses the first three BRC repeats (34). The abrogation of embryonic lethality by *Brca2*^{tm1Cam} (8) compared with other truncating mutations that delete exon 11 of all BRC repeats (7) strongly suggests that the remaining 3 BRC repeats in the




FIG. 2. Radiation-induced Rad51 foci were diminished in cells expressing wild-type GFP-BRC4. A, WT-8 and MT-11 cells (indicated in the left margin) were cultured in the presence (+) or absence (-) of tetracycline (*Tet*) for 48 h and then exposed to 12-Gy γ -radiation. Irradiated cells after 6 h were immunostained with α -Rad51 and Texas Red-conjugated secondary antibody. Expression of wild-type and mutant GFP-BRC4 was visualized by GFP autofluorescence. Panels a and c show the radiation-induced Rad51 foci overlaid with DAPI in the uninduced cells (+*Tet*). Panels b and d show the radiation-induced Rad51 foci overlaid with GFP autofluorescence in the induced cells (-*Tet*). Note the radiation-induced Rad51 foci were diminished in the wild-type GFP-BRC4 expressing cells (panel b) compared with panel d). B, images containing 250 cells were captured by computer, and the number of cells containing at least 10 foci were recorded and plotted as a percentage of total cells. The plots were generated from two independent experiments.

Brca2^{tm1Cam} truncated protein are partially functional. The functional importance of the BRC repeats is supported by our results demonstrating that the expression of GFP-BRC4 repeat in cells results in hypersensitivity to radiation and a failure in G_2/M checkpoint control. The increased radiosensitivity in cells expressing the BRC4 repeat indicates that the complex of BRCA2 and Rad51 is important for the mechanics of the repair process. This notion is compatible with the known role of Rad51 in recombination repair. In this capacity, BRCA2 may facilitate Rad51 function in strand exchange by modulating formation of the Rad51-DNA nucleoprotein filament and/or pairing and strand-exchange steps of DNA double strand break repair (13).

The failure of radiation-induced G_2/M checkpoint control in cells expressing BRC4 repeat indicates that BRCA2 may have a role in this task. It is possible that the formation of the BRCA2 and Rad51 complex could be important for radiation-induced G_2/M checkpoint control. However, the BRCA2-Rad51 complex is formed independently of DNA damage (10–12). Other G_2/M checkpoint proteins may be required to participate in the BRCA2-Rad51 complex. Interestingly, mouse embryo fibroblasts expressing exon 11-deleted *Brca1* also exhibit defects in radiation-induced G_2/M checkpoint control (28) and BRCA2 apparently interacts with BRCA1 (35). It is possible, therefore, that the BRCA2-Rad51 complex may interact with




FIG. 3. Cells expressing GFP-BRC4 show intact G_1/S and defective G_2/M checkpoints. A, G_1/S checkpoint in γ -irradiated cells. WT-8 and MT-11 cells were incubated with (+) or without (-) tetracycline for 24 h and then mock-exposed (0 Gy) or γ -irradiated (12 Gy). Cells were labeled 24 h later with BrdUrd for 4 h and immunostained with α -BrdUrd antibody. The percentage of BrdUrd-positive cells was quantified and expressed as a fraction of the total number of cells. Note that the relative percentage of BrdUrd-positive cells decreases significantly in cells expressing both wild-type (WT-8) and mutated (MT-11) GFP-BRC4 following radiation, indicative of intact G_1/S checkpoint in these cells. B, defective G_2/M checkpoint in cells expressing wild-type GFP-BRC4. Mitotic cells were counted at 1–5 h after exposure to 3 Gy γ -radiation (panel a) or at 1 h after exposure to 4–16 Gy (panel b). Mitotic indices of mock-exposed cells were used as controls. Over 2000 cells were counted at each exposure and time point.

BRCA1 to establish G_2/M checkpoint control. Alternatively, the BRC repeats may mediate separate interactions with cell cycle checkpoint proteins when induced by DNA damage signaling.

Regardless of which possibility is operative in cells, the data presented here support and extend the model originally proposed (10), that BRC repeat interactions with Rad51 are important for the cellular DNA damage response. The observation that *mRad51^{-/-}* mouse embryos are not viable and ES cells with the same genotype cannot survive (16, 17), coupled with the observation that *Brca2^{tm1Cam}* cells are viable but radiation-sensitive (8), suggests that Rad51, through interactions with BRCA2, may have functions in addition to DNA repair. Like, BRCA1, it appears that BRCA2 functions in a pathway that bifurcates into one that is important for repair of genetic lesions and another important for restraining cell division until repair is complete. It is possible that each of the BRC repeats, or certain group of the repeats, may have separate and distinct functions within each pathway. Nevertheless, the fact that expression of one BRC repeat can disrupt Rad51-BRCA2 interactions, interfere with the G_2/M checkpoint, and can make cells radiation-sensitive suggests that it could be used to radiosensitize and/or chemosensitize resistant tumors.

Acknowledgments—We thank Drs. Yumay Chen and Tom Boyer for their critical reading this manuscript and assistance for the experiments. We are also grateful for Dr. Alex Nikitin for his kind help in the statistic analyses.

REFERENCES

1. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., Barfoot, R., Hamoudi, R., Patel, S., Rice, C., Biggs, P., Hashim, Y., Smith, A., Connor, F., Arason, A., Gudmundsson, J., Ficenec, D., Kelsell, D., Ford, D., Tonin, P., Bishop, D. T., Spurr, N. K., Ponder, B. A. J., Eeles, R., Peto, J., Devilee, P., Cornelisse, C., Lynch, H., Narod, S., Lenoir, G., Egilsson, V., Barkadottir, R. B., Easton, F. E., Bentley, D. R., Futreal, P. A., Ashworth, A., and Stratton, M. R. (1995) *Nature* **378**, 789–792.
2. Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., Jammulapati, S., Janek, T., Jiang, P., Kehrer, R.,

- and Leblanc, J. F. (1996) *Nat. Genet.* **12**, 333-337
3. Marquis, S. T., Rajan, J. V., Wynshaw-Boris, A., Xu, J., Yin, G. Y., Abel, K. J., Weber, B. L., and Chodosh, L. A. (1995) *Nat. Genet.* **11**, 17-26
 4. Rajan, J. V., Wang, M., Marquis, S. T., and Chodosh, L. A. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 13078-13083
 5. Rajan, J. V., Marquis, S. T., Gardner, H. P., and Chodosh, L. A. (1997) *Dev. Biol.* **184**, 385-401
 6. Vaughn, J. P., Cirisano, F. D., Huper, G., Berchuck, A., Futreal, P. A., Marks, J. R., and Iglehart, J. D. (1996) *Cancer Res.* **56**, 4590-4594
 7. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. (1997) *Nature* **386**, 804-810
 8. Patel, K. J., Vu, V. P., Lee, H., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A., and Venkitaraman, A. R. (1998) *Mol. Cell* **1**, 347-357
 9. Abbott, D. W., Freeman, M. L., and Holt, J. T. (1998) *J. Natl. Cancer Inst.* **90**, 978-985
 10. Chen, P. L., Chen, C. F., Chen, Y., Xiao, J., Sharp, Z. D., and Lee, W. H. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 5287-5292
 11. Mizuta, R., LaSalle, J. M., Cheng, H. L., Shinohara, A., Ogawa, H., Copeland, N., Jenkins, N. A., Lalande, M., and Alt, F. W. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 6927-6932
 12. Wong, A. K. C., Pero, R., Ormonde, P. A., Tavtigian, S. V., and Bartel, P. L. (1997) *J. Biol. Chem.* **272**, 31941-31944
 13. Shinohara, A., Ogawa, H., and Ogawa, T. (1992) *Cell* **69**, 457-470
 14. Baumann, P., Benson, F. E., and West, S. C. (1996) *Cell* **87**, 757-766
 15. Baumann, P., and West, S. C. (1997) *EMBO J.* **16**, 5198-5206
 16. Lim, D. S., and Hasty, P. (1996) *Mol. Cell. Biol.* **16**, 7133-7143
 17. Tsuzuki, T., Fujii, Y., Sakumi, K., Tominaga, Y., Nakao, K., Sekiguchi, M., Yoshimura, Y., and Morita, T. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 6236-6240
 18. Shen, Z., Cloud, K. G., Chen, D. J., and Park, M. S. (1996) *J. Biol. Chem.* **271**, 148-152
 19. Bork, P., Blomberg, N., and Nilges, M. (1996) *Nat. Genet.* **13**, 22-23
 20. Bignell, G., Micklem, G., Stratton, M. R., Ashworth, A., and Wooster, R. (1997) *Hum. Mol. Genet.* **6**, 53-58
 21. Shan, B., Durfee, T., and Lee, W. H. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 679-684
 22. Durfee, T., Becherer, K., Chen, P.-L., Yeh, S.-H., Yang, Y., Kilburn, A. E., Lee, W.-H., and Elledge, S. J. (1993) *Genes Dev.* **7**, 555-569
 23. Vidal, M., Braun, P., Chen, E., Boeke, J. D., and Harlow, E. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 10321-10326
 24. Gossen, M., and Bujard, H. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 5547-5551
 25. Evan, G. I., Lewis, G. K., Ramsay, G., and Bishop, J. M. (1985) *Mol. Cell. Biol.* **5**, 3610-3616
 26. Zhong, Q., Chen, C.-F., Li, S., Chen, Y., Wang, C.-C., Xiao, J., Chen, P.-L., Sharp, Z. D., and Lee, W.-H. (1999) *Science* **285**, 747-750
 27. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 7491-7495
 28. Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T., and Deng, C. X. (1999) *Mol. Cell* **3**, 389-395
 29. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Vogelstein, B., and Fornace, A. J., Jr. (1992) *Cell* **71**, 587-597
 30. Lu, X., and Lane, D. P. (1993) *Cell* **75**, 765-778
 31. Brugarolas, J., and Jacks, T. (1997) *Nat. Med.* **3**, 721-722
 32. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. (1995) *Cell* **82**, 675-684
 33. Elledge, S. J. (1996) *Science* **274**, 1664-1672
 34. Friedman, L. S., Thistlethwaite, F. C., Patel, K. J., Yu, V. P., Lee, H., Venkitaraman, A. R., Abel, K. J., Carlton, M. B., Hunter, S. M., Colledge, W. H., Evans, M. J., and Ponder, B. A. (1998) *Cancer Res.* **58**, 1338-1343
 35. Chen, J., Silver, D. P., Walpita, D., Cantor, S. B., Gazdar, A. F., Tomlinson, G., Couch, F. J., Weber, B. L., Ashley, T., Livingston, D. M., and Scully, R. (1998) *Mol. Cell* **2**, 317-328